Key facts
- BM Diagnostics’s last known valuation is $4.1M (Feb 2025).
- It has raised $540K; the latest was Accelerator/Incubator in Jan 2026.
- Notable investors include LvlUp Ventures, gBETA, Bravo Innovation Hub, IKIGAI (Siena), Novella Center for Entrepreneurship — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for BM Diagnostics
- ·The full record, as it builds
Funding rounds
No funding rounds for BM Diagnostics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About BM Diagnostics
Developer of a health-care products designed to make diagnostic tests and preventive healthcare more accessible. The company offers rapid diagnostic kits, wellness supplements, and the heartbeat test, enabling healthcare centers to monitor and manage patient well-being with improved health outcomes.
- Sector
- Healthcare
- HQ
- Cantiano, Italy
- Founded
- 2023
- Employees
- 3
- Website
- bmdiagnostics.it/
- Ownership
- Privately Held (backing)
BM Diagnostics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BM Diagnostics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BM Diagnostics in its N-PORT filings yet. We sweep new filings monthly.